Loading
A phase 3 trial of Dexamethasone, Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by National Cancer Institute (NCI), completed.
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT00033332 by National Cancer Institute (NCI), started 2002-04 and reaching its primary completion in 2006-03. Interventions recorded: dexamethasone, pamidronate disodium, thalidomide, zoledronic acid. Conditions recorded: Multiple Myeloma and Plasma Cell Neoplasm.
Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Shares Pamidronate, Thalidomide, Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Pamidronate, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.